Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.

NCT01598831 is registered in ClinicalTrials.gov with Asahi Kasei Pharma America Corporation as lead sponsor.

NCT NCT01598831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01598831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.
Lead sponsor
Asahi Kasei Pharma America Corporation
Phase
Phase 3
Overall status
Completed
Start date
October 29, 2012
Completion date
February 28, 2019
Enrollment
816 (actual)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

coagulopathy, severe sepsis